| 2.83 -0.025 (-0.88%) | 04-26 10:49 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 4.56  |
1-year : | 5.4 |
| Resists | First : | 3.91 |
Second : | 4.63 |
| Pivot price | 3.53 |
|||
| Supports | First : | 2.75 |
Second : | 2.28 |
| MAs | MA(5) : | 3.1 |
MA(20) : | 3.67 |
| MA(100) : | 3.8  |
MA(250) : | 4.08 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 3.6 |
D(3) : | 1.9 |
| RSI | RSI(14): 21.3 |
|||
| 52-week | High : | 6.88 | Low : | 2.23 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ALLO ] has closed above bottom band by 8.5%. Bollinger Bands are 39.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.99 - 3.02 | 3.02 - 3.03 |
| Low: | 2.79 - 2.81 | 2.81 - 2.84 |
| Close: | 2.82 - 2.85 | 2.85 - 2.88 |
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Fri, 26 Apr 2024
Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to ... - WDRB
Wed, 24 Apr 2024
Allogene Therapeutics (ALLO) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
Mon, 22 Apr 2024
Allogene Therapeutics (ALLO) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Movies UK
Tue, 09 Apr 2024
Allogene Therapeutics Announces Q2 Investor Conference Participation - Investor Relations | Allogene Therapeutics
Mon, 08 Apr 2024
How Allogene (ALLO) Stock Stands Out in a Strong Industry - Yahoo Finance
Sun, 07 Apr 2024
We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 169 (M) |
| Held by Insiders | 1.11e+008 (%) |
| Held by Institutions | 22.4 (%) |
| Shares Short | 25,010 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.0029e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 163 % |
| Return on Assets (ttm) | 475 % |
| Return on Equity (ttm) | -26.9 % |
| Qtrly Rev. Growth | 95000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -69.39 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -2.1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -238 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | -2.1 |
| Price to Book value | 0 |
| Price to Sales | -0.05 |
| Price to Cash Flow | 0.75 |
| Dividend | 0 |
| Forward Dividend | 3.062e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|